Trials / Conditions / Unresectable Renal Cell Carcinoma

Unresectable Renal Cell Carcinoma

12 registered clinical trials studyying Unresectable Renal Cell Carcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256	City of Hope Medical Center	Phase 1
Withdrawn	Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Meta NCT06603155	Duke University	N/A
Recruiting	Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With NCT05327686	NRG Oncology	Phase 2
Recruiting	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381	Mayo Clinic	Phase 1 / Phase 2
Active Not Recruiting	CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cance NCT05122546	City of Hope Medical Center	Phase 1
Withdrawn	Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer NCT04603365	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer NCT04337970	Memorial Sloan Kettering Cancer Center	Phase 1 / Phase 2
Completed	CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer NCT03829111	City of Hope Medical Center	Phase 1
Active Not Recruiting	A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124	National Cancer Institute (NCI)	Phase 2
Terminated	Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastat NCT03334409	Academic and Community Cancer Research United	Phase 2
Completed	Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed NCT02761057	National Cancer Institute (NCI)	Phase 2
Terminated	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495	M.D. Anderson Cancer Center	Phase 1